Sanofi: Libtayo approved in advanced BCC in the US
(CercleFinance.com) - Sanofi has announced the approval by the US FDA of PD-1 Inhibitor Libtayo (cemiplimab-rwlc), Becoming the first immunotherapy drug Indicated for the treatment of patients with advanced basal cell carcinoma (BCC).
The French healthcare group says full approval has been granted for patients with locally advanced BCC and accelerated approval has been granted for patients with metastatic BCC.
This approval in the United States follows a priority review by the FDA, a procedure reserved for drugs representing a significant improvement in terms of safety or efficacy for the treatment of serious diseases.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The French healthcare group says full approval has been granted for patients with locally advanced BCC and accelerated approval has been granted for patients with metastatic BCC.
This approval in the United States follows a priority review by the FDA, a procedure reserved for drugs representing a significant improvement in terms of safety or efficacy for the treatment of serious diseases.
Copyright (c) 2021 CercleFinance.com. All rights reserved.